N@N

Sumant Kulkarni Initiated (BIIB) at Hold and Held Target at $340 on, Oct 27th, 2017

Sumant Kulkarni of Canaccord Genuity, Initiated "Biogen Inc." (BIIB) at Hold and Held Target at $340 on, Oct 27th, 2017.

Sumant has made no other calls on BIIB in the last 4 months.

There are 12 other peers that have a rating on BIIB. Out of the 12 peers that are also analyzing BIIB, 4 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Carter Gould of "UBS" Maintained at Hold with Increased Target to $318 on, Wednesday, October 25th, 2017
• Robyn Karnauskas of "Citigroup" Downgraded from Strong Buy to Hold on, Monday, October 23rd, 2017
• Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $319 on, Friday, September 15th, 2017
• Eun Yang of "Jefferies" Initiated at Hold and Held Target at $310 on, Tuesday, July 11th, 2017

These are the ratings of the 8 analyists that currently disagree with Sumant

---

• Jeffrey Silber of "BMO Capital" Upgraded from Hold to Buy on, Wednesday, October 25th, 2017
• Adnan Butt of "Guggenheim" Initiated at Strong Buy and Held Target at $402 on, Tuesday, October 24th, 2017
• Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $390 on, Monday, October 23rd, 2017
• Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $365 on, Wednesday, October 18th, 2017
• Thomas Shrader of "Stifel" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Salim Syed of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, October 17th, 2017
• Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Thursday, October 5th, 2017
• Terence Flynn of "Goldman Sachs" Upgraded at Strong Buy on, Wednesday, August 16th, 2017

Contributing Sources

---